Pharmaceutical Sector

Novartis’ experimental cancer treatment wins endorsement of FDA advisers

The U.S. Food & Drug Administration (FDA) on Wednesday endorsed a first-of-its-kind cancer treatment that makes use of patients’ revved-up immune cells to fight back the deadly disease.

FDA approves new epinephrine injector from Adamis Pharmaceuticals

The U.S. Food & Drug Administration (FDA) has finally approved a new epinephrine injector for anaphylaxis, increasing competition for the controversially expensive injector EpiPen.

New Heart Failure Drug Marketing Costs to Alleviate Novartis’ 2016 Profit

Novartis revealed on Tuesday that the company is boosting its expenditure on marketing a new heart failure drug called Entresto subsequent to disappointing initial sales of the medicine. This increase in expenditure might have a dampening impact on the profit of Novartis in 2016.

German drugmaker Merck’s experimental cancer medicine evofosfamide fails in last stage of clinical tests

German drugmaker Merck said that its experimental cancer medicine evofosfamidehas failed in the last stage of clinical tests due to which it won't seek regulatory approval for its treatment.

On Monday, Darmstadt, Germany-based Merck said in a statement that the medicine wasn’t helpful for patients, having pancreatic cancer or soft-tissue sarcoma live longer when taken along with chemotherapy.

Pages